GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Labiana Health SA (XMAD:LAB) » Definitions » Current Deferred Revenue

Labiana Health (XMAD:LAB) Current Deferred Revenue : €0.00 Mil (As of Dec. 2022)


View and export this data going back to 2022. Start your Free Trial

What is Labiana Health Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Labiana Health's current deferred revenue for the quarter that ended in Dec. 2022 was €0.00 Mil.

Labiana Health Current Deferred Revenue Historical Data

The historical data trend for Labiana Health's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Labiana Health Current Deferred Revenue Chart

Labiana Health Annual Data
Trend Dec20 Dec21 Dec22
Current Deferred Revenue
- - -

Labiana Health Semi-Annual Data
Dec20 Dec21 Jun22 Dec22
Current Deferred Revenue - - - -

Labiana Health Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Labiana Health's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Labiana Health (XMAD:LAB) Business Description

Traded in Other Exchanges
N/A
Address
Avenida Europa, 34 1st D, Pozuelo de Alarcon, Madrid, ESP, 28023
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include GMP manufacturer for EU animal and human health industries, manufacturer specialized in sterile and lyophilized dosage forms, source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol.